Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Alzheimer's Disease
Interventions
DRUG

simufilam

simufilam 100 mg oral tablet, twice daily

Trial Locations (11)

33157

IMIC Research, Palmetto Bay

33445

Brain Matters Research, Delray Beach

33912

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

43221

the Ohio State University, Columbus

68046

Cognitive Clinical Trials, Papillion

78757

Senior Adults Specialty Research, Austin

85296

Cognitive Clinical Trials, Gilbert

92251

Valley Research Center, Inc., Imperial

08755

Advanced Memory Research Institute of NJ, Toms River

K1Z1G3

Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic, Ottawa

M3B 2S7

Toronto Memory Program ULC, Toronto

Sponsors
All Listed Sponsors
lead

Cassava Sciences, Inc.

INDUSTRY

NCT05352763 - Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter